Shah Neeraj Mukesh, D'Cruz Rebecca Francesca, Murphy Patrick B
Lane Fox Respiratory Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
J Thorac Dis. 2018 Jan;10(Suppl 1):S71-S79. doi: 10.21037/jtd.2017.10.44.
Chronic obstructive pulmonary disease (COPD) remains a common cause of morbidity and mortality worldwide. Patients with COPD and respiratory failure, whether acute or chronic have a poorer prognosis than patients without respiratory failure. Non-invasive ventilation (NIV) has been shown to be a useful tool in both the acute hospital and chronic home care setting. NIV has been well established as the gold standard therapy for acute decompensated respiratory failure complicating an acute exacerbation of COPD with reduced mortality and intubation rates compared to standard therapy. However, NIV has been increasingly used in other clinical situations such as for weaning from invasive ventilation and to palliate symptoms in patients not suitable for invasive ventilation. The equivocal evidence for the use of NIV in chronic hypercapnic respiratory failure complicating COPD has recently been challenged with data now supporting a role for therapy in selected subgroups of patients. Finally the review will discuss the emerging role of high flow humidified therapy to support or replace NIV in certain clinical situation.
慢性阻塞性肺疾病(COPD)仍是全球发病和死亡的常见原因。患有COPD和呼吸衰竭的患者,无论急性还是慢性,其预后都比没有呼吸衰竭的患者更差。无创通气(NIV)已被证明在急性医院和慢性家庭护理环境中都是一种有用的工具。NIV已被确立为急性失代偿性呼吸衰竭的金标准治疗方法,与标准治疗相比,它可使因COPD急性加重而并发急性失代偿性呼吸衰竭的患者死亡率和插管率降低。然而,NIV越来越多地用于其他临床情况,例如从有创通气中撤机以及缓解不适合有创通气患者的症状。最近,关于NIV用于并发COPD的慢性高碳酸血症呼吸衰竭的证据并不明确,现有数据对其提出了挑战,这些数据现在支持在特定亚组患者中进行治疗。最后,本综述将讨论高流量湿化疗法在某些临床情况下支持或替代NIV的新作用。